Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
Part of paid clinical trials in Los Angeles, California.
- Sponsor
- National Cancer Institute (NCI)
- Study ID
- NCT00748657
- Phase
- PHASE2
- Status
- Completed
Conditions
- Malignant Ovarian Epithelial Tumor
- Ovarian Granulosa Cell Tumor
- Ovarian Gynandroblastoma
- Ovarian Sertoli-Leydig Cell Tumor
- Ovarian Sex Cord Tumor With Annular Tubules
- Ovarian Sex Cord-Stromal Tumor
- Ovarian Sex Cord-Stromal Tumor of Mixed or Unclassified Cell Types
- Ovarian Steroid Cell Tumor
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Bevacizumab — BIOLOGICALGiven IV
- Laboratory Biomarker Analysis — OTHERCorrelative studies
Study Details
This phase II trial studies how well bevacizumab works in treating patients with sex cord-stromal tumors of the ovary that have come back. Monoclonal antibodies, such as bevacizumab, may block tumor growth in different ways by targeting certain cells. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor.
Key Dates
- First listed
- Sep 8, 2008
- Start date
- Sep 22, 2008
- Status verified
- Jul 2019
- Primary completion
- Jan 31, 2013
- Completion
- Jan 31, 2013
Study Design
- Enrollment
- 36 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Treatment (bevacizumab)Patients receive bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Primary Outcome Measure
Tumor Response [ Time Frame: Every other cycle for 6 months; then every 3 months for two years; then every six months for three years; and at any other time if clinically indicated based on symptoms, physical signs suggestive of progressive disease or rising serum tumor maker levels ]
Locations (36)
Find similar trials in Los Angeles, CA
By research site
Related Studies
- ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian CancerPHASE2 · Recruiting · Ira Winer · Detroit, Michigan